Close Menu

NEW YORK — Digital pathology firm HistoIndex said on Tuesday that it has joined an international consortium focused on developing a computational tool for identifying nonalcoholic fatty liver disease (NAFLD) patients at high risk of progressing to nonalcoholic steatohepatitis (NASH).

The consortium, called INTErPRET-NAFLD, is led by the University of Edinburgh and recently received €750,000 ($910,270) in research funding from Eureka Globalstars, Enterprise Singapore, and Innovate UK, according to Singapore-based HistoIndex.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.